Portela nears EU approval: Will Zoetis’ quarterly cat pain injection reshape veterinary care?

Zoetis Inc. (NYSE: ZTS) has received a positive opinion from the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA) for Portela (relfovetmab), a novel monoclonal antibody (mAb) treatment designed to manage pain from osteoarthritis (OA) in cats. The recommendation moves the animal health giant one step closer to launching what could be the first long-acting anti-nerve growth factor (NGF) therapy tailored specifically for feline patients in Europe.

If authorized by the European Commission later this year, Portela will offer veterinarians and pet owners a science-backed, once-every-three-month solution for treating a condition that affects an estimated 40% of cats, yet often goes undiagnosed.

What makes Portela a breakthrough for cats suffering from chronic osteoarthritis pain?

Portela’s proposed label sets it apart as a long-acting monoclonal antibody targeting NGF, a key driver of chronic pain in osteoarthritic conditions. A single subcutaneous injection is expected to deliver three months of pain relief, helping simplify treatment regimens—particularly for pet owners who struggle to medicate their cats regularly.

The EMA’s CVMP issued the recommendation based on robust safety and efficacy data, including trials involving cats diagnosed with mild to moderate kidney disease (IRIS stages 1–3). These studies indicated a positive benefit-risk profile, showing that Portela was well-tolerated and successfully alleviated OA pain across a range of clinical indicators.

Zoetis Executive Vice President and R&D head Rob Polzer stated that the long-acting nature and novel NGF-binding site of Portela are likely to bring measurable improvements in quality of life for cats. He emphasized the significance of this milestone in expanding Zoetis’ role in feline pain management, especially within the European Union.

How large is the unmet need for osteoarthritis pain management in cats—and why has it been overlooked?

Osteoarthritis is a chronic, degenerative joint disease characterized by cartilage breakdown, inflammation, and reduced mobility. While the condition is well recognized in dogs and humans, feline OA has remained underdiagnosed and undertreated for decades. Studies suggest that up to 4 in 10 cats show clinical signs of OA, but fewer than 20% of these are formally diagnosed by veterinary professionals.

The signs—such as reduced activity, reluctance to jump, or subtle behavioral changes—are frequently dismissed as signs of aging by pet owners. Yet chronic OA pain can have wide-ranging effects on a cat’s physical and emotional wellbeing, impairing sleep, cognition, appetite, and social behaviors.

Zoetis highlights that Portela, if approved, would be a critical tool in closing this diagnosis-treatment gap. Its quarterly dosing schedule is expected to lower barriers to consistent care, making it easier for veterinarians to recommend treatment and for owners to follow through.

How does Portela compare with Solensia and what does this mean for Zoetis’ OA pain franchise?

Portela’s debut would not be Zoetis’ first foray into NGF-targeting monoclonal antibodies. The company already markets Solensia (frunevetmab), a once-monthly mAb therapy for OA pain in cats, currently approved in over 40 countries. Solensia has been adopted by veterinary clinics worldwide and has amassed over four years of real-world usage data, showing consistent efficacy in reducing feline pain and improving mobility.

While both Portela and Solensia share the same therapeutic class—anti-NGF antibodies—Portela is uniquely positioned for quarterly administration, offering greater convenience and potentially improved compliance. Richard Goldstein, Zoetis’ Global Chief Medical Officer, noted that this reduced frequency could enhance owner satisfaction and veterinary workflow, while delivering sustained pain control for the cat.

The addition of Portela would further diversify and fortify Zoetis’ OA pain franchise, a category the firm is actively expanding through both lifecycle innovation and new molecular entities. Goldstein also positioned the therapy as part of Zoetis’ broader commitment to science-led solutions addressing unmet medical needs in animal care.

What are the next regulatory steps before Portela becomes commercially available in the European Union?

With the CVMP recommendation in hand, Zoetis now awaits formal marketing authorization from the European Commission, a process expected to conclude by the fourth quarter of 2025. The American animal health company anticipates launching Portela commercially in 2026 across European Union markets, subject to final approval.

Veterinarians across Europe are expected to welcome the therapy as part of a broader movement toward biologic-based pain management options, especially those that align with newer understandings of chronic pain pathways in companion animals. Portela’s approval would further reinforce the EU’s openness to novel veterinary biologics, particularly those backed by robust clinical safety and efficacy evidence.

How does Zoetis plan to expand its leadership in animal biologics and companion animal care?

Zoetis has long positioned itself as a pioneer in animal health biologics, with a global product portfolio that includes vaccines, diagnostics, and monoclonal antibodies. In 2024, the company reported USD 9.3 billion in revenue, supported by approximately 13,800 employees and a presence in over 100 countries.

Portela fits squarely into the firm’s strategy to grow its biologics footprint through both therapeutic innovation and geographic expansion. Alongside Solensia for cats and Librela for dogs, the firm is building a multi-species NGF-targeting platform, targeting chronic pain in both companion and livestock animals.

Institutional sentiment toward Zoetis remains broadly positive. Analysts view the approval path for Portela as a validation of Zoetis’ continued dominance in veterinary monoclonal antibody development, an area where few competitors have demonstrated comparable R&D depth. The firm’s focus on lifecycle innovation and regulatory execution remains a key differentiator in a sector increasingly influenced by biotech-style pipelines.

What is the longer-term outlook for Zoetis and its biologic therapies like Portela and Solensia?

With Portela expected to reach the European market in 2026, and Solensia already established across key territories, Zoetis is well-positioned to capture expanding demand for feline pain therapeutics, particularly those grounded in immunological science. Analysts expect the dual positioning of monthly and quarterly mAb therapies to enable flexible treatment strategies, giving veterinarians multiple tools to personalize care.

Future growth will likely depend on the firm’s ability to maintain regulatory momentum, expand access across additional markets, and possibly pursue label extensions or lifecycle enhancements for its flagship mAb products. As chronic pain in companion animals gains broader recognition, particularly in aging pet populations, biologics like Portela may well become the standard of care.